According to Zhitong Finance App, Rongchang Biotech (09995) announced that for the first three quarters of 2026, operating income was 6.764 billion yuan, an increase of 293.28% over the previous year; net profit attributable to shareholders of listed companies was 5.273 billion yuan, loss of 551 million yuan for the same period last year; and basic earnings per share were 9.41 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.